Abstract Background Though often overlooked, calming patients and increasing their life engagement are key factors in the treatment of major
Highlights • This study evaluated chronobiologic sleep parameters in major depressive disorder. • Nine depressed patients received open-label adjunctive brexpiprazole
Abstract Purpose/Background Evidence supports use of adjunctive atypical antipsychotics in major depressive disorder (MDD). Impaired sexual functioning is common in
Abstract Objective: To analyze the effect of adjunctive brexpiprazole on metabolic parameters and body weight in adults with major depressive disorder
Abstract Background: There is a need for effective, safe and well-tolerated pharmacotherapies for patients with major depressive disorder (MDD) who
Abstract Background Long-term treatment is recommended in major depressive disorder (MDD) to prevent relapse and to restore functioning. The aim
Abstract Objective Episodes of major depressive disorder (MDD) characterized by high levels of anxiety symptoms are less likely to respond
Abstract Objectives The objective of this study was to evaluate the long‐term safety and tolerability of flexible‐dose brexpiprazole adjunct to
Implications/conclusions: Differences in tolerability profiles regarding activation and sedation have implications in terms of selecting the optimal antipsychotic for
Abstract Objective: To evaluate the effects of adjunctive brexpiprazole on symptoms of irritability in patients with major depressive disorder (MDD). להמשך
